Vitamin D deficiency is among the most common and clinically significant nutritional abnormalities in chronic kidney disease (CKD), affecting an estimated 70–80% of CKD patients by some measures — yet managing vitamin D in CKD is more complex than simply prescribing a standard supplement. The kidneys play a central role in converting vitamin D into its active form, and as kidney function declines, this conversion process becomes progressively impaired. At the same time, disordered vitamin D metabolism drives the bone disease, cardiovascular complications, and immune dysfunction that contribute to morbidity in CKD. Understanding what vitamin D does, why CKD disrupts its metabolism so fundamentally, what forms of vitamin D supplementation are appropriate and when, and what the evolving research on vitamin D and CKD outcomes shows is essential for patients and their care teams. This article provides a comprehensive overview of vitamin D and kidney disease — from biochemistry through clinical practice. For the context of how vitamin D and calcium interact with kidney disease, the companion article on kidney disease and mineral balance covers the full calcium-phosphorus-PTH-vitamin D system in CKD in detail. The article on supplements for kidney health covers the general framework for evaluating supplement safety in CKD patients, including the vitamin D family of supplements.
Vitamin D Metabolism and Why CKD Disrupts It
Vitamin D metabolism involves a sequence of activation steps in the skin, liver, and kidneys — and CKD disrupts the final and most critical step. Understanding this pathway explains why standard vitamin D supplements are often insufficient in CKD and why the form of supplementation matters enormously. The three-step activation pathway: the first step occurs in the skin, where ultraviolet B radiation from sunlight converts 7-dehydrocholesterol (a cholesterol precursor) into cholecalciferol (vitamin D3). Vitamin D3 can also be obtained from dietary sources including fatty fish, egg yolks, and fortified foods, and from vitamin D supplements (either D2 ergocalciferol or D3 cholecalciferol). The second step occurs in the liver, where vitamin D3 is hydroxylated by the enzyme CYP2R1 to produce 25-hydroxyvitamin D (25-OHD, also called calcidiol). This is the form measured by the standard “vitamin D blood test” (serum 25-OHD level) and the form that serves as the main circulating storage form of vitamin D. Liver disease can impair this step, but it is generally intact in CKD. The third step occurs primarily in the kidneys — specifically in the proximal tubular cells — where the enzyme CYP27B1 (1-alpha-hydroxylase) converts 25-OHD into 1,25-dihydroxyvitamin D (calcitriol), the hormonally active form of vitamin D. Calcitriol is the form that activates vitamin D receptors throughout the body, regulating calcium absorption in the gut, calcium and phosphorus reabsorption in the kidneys, PTH suppression in the parathyroid glands, and numerous other cellular functions. Why CKD impairs this pathway at the kidney step: as CKD progresses and nephron mass declines, there are progressively fewer proximal tubular cells capable of producing calcitriol. The result is calcitriol deficiency — even when serum 25-OHD levels are adequate — because the kidney cannot convert the available precursor into the active hormone. The impaired calcitriol production leads to reduced intestinal calcium absorption (hypocalcemia), which stimulates the parathyroid glands to increase PTH secretion (secondary hyperparathyroidism). Elevated PTH stimulates bone resorption to release calcium, contributing to renal osteodystrophy. Elevated phosphate levels (due to reduced kidney excretion) stimulate FGF-23 production, which further suppresses calcitriol synthesis, creating a vicious cycle: high FGF-23 → low calcitriol → high PTH → bone resorption → elevated phosphate → higher FGF-23. The two distinct vitamin D deficiencies in CKD: patients with CKD can have two separate vitamin D-related problems that require different treatments. First, nutritional vitamin D deficiency — low serum 25-OHD levels due to insufficient sunlight, dietary intake, or absorption — which is common in CKD patients partly because many CKD-appropriate diets restrict foods high in vitamin D, and partly because reduced outdoor activity limits sunlight exposure. This can be treated with standard vitamin D3 supplements. Second, CKD-specific calcitriol deficiency — impaired conversion of 25-OHD to calcitriol by the damaged kidneys — which standard vitamin D3 supplements cannot adequately correct because the conversion step is blocked. This requires treatment with activated vitamin D preparations (calcitriol, alfacalcidol, or paricalcitol) that bypass the kidney activation step. The NIDDK information on kidney disease and bone disease is available at the NIDDK mineral and bone disorder page.
Clinical Management of Vitamin D in CKD: What Treatment Looks Like
The clinical management of vitamin D deficiency in CKD is guided by the KDIGO (Kidney Disease Improving Global Outcomes) CKD-Mineral and Bone Disorder (CKD-MBD) guidelines, which provide evidence-based recommendations for monitoring and treating the vitamin D–PTH–calcium–phosphorus axis across CKD stages. Understanding the treatment framework helps patients engage meaningfully with their care team about vitamin D management. Monitoring targets and frequency: in CKD stages G3a through G5 (not on dialysis), KDIGO recommends monitoring serum calcium, phosphate, PTH, and 25-OHD at intervals determined by CKD stage and degree of abnormality. Serum 25-OHD is the appropriate screening test for nutritional vitamin D deficiency, and the conventional threshold for deficiency is below 20 ng/mL (50 nmol/L), with insufficiency at 20–30 ng/mL. However, the target 25-OHD range in CKD is a subject of ongoing debate — some evidence suggests that in CKD the relationship between serum 25-OHD and calcitriol production is different enough from the general population that the standard targets may need adjustment. The nephrology team will generally define appropriate target ranges for the individual patient based on CKD stage, PTH level, and other factors. Treating nutritional vitamin D deficiency: if serum 25-OHD is low (below 20 ng/mL) in a CKD patient who does not yet have severe secondary hyperparathyroidism, supplementation with native vitamin D3 (cholecalciferol) is typically recommended. Doses range from 800–4000 IU daily depending on baseline level and CKD stage. The goal is to correct the nutritional deficiency and normalize serum 25-OHD — this restores the substrate available for whatever kidney activation capacity remains, particularly relevant in earlier CKD stages (G3a–G3b) where significant calcitriol production capacity is still present. Activated vitamin D therapy for secondary hyperparathyroidism: in CKD patients with elevated PTH despite adequate 25-OHD levels, or in more advanced CKD (stage G4–G5) where calcitriol production is severely impaired, treatment with activated vitamin D analogues is typically prescribed. Calcitriol (1,25-dihydroxyvitamin D3, the natural active form) and alfacalcidol (1-alpha-hydroxyvitamin D3, activated to calcitriol in the liver) directly suppress PTH by activating vitamin D receptors in the parathyroid glands. Selective vitamin D receptor activators (VDRAs) including paricalcitol and doxercalciferol suppress PTH with potentially less impact on calcium and phosphorus absorption — a concern with calcitriol because over-suppression of PTH combined with calcium and phosphorus loading can contribute to vascular calcification. The balance between PTH suppression and hypercalcemia/hyperphosphatemia risk: the central clinical tension in managing vitamin D in CKD is between adequate PTH suppression (to prevent renal osteodystrophy and its fracture, bone pain, and vascular calcification consequences) and avoiding the hypercalcemia and hyperphosphatemia that can result from over-aggressive vitamin D therapy. Both extremes — undertreated high PTH and overtreated low PTH (adynamic bone disease) — carry risks. This is why vitamin D management in CKD is not a “more is better” situation and why taking over-the-counter activated vitamin D or high-dose standard vitamin D without medical supervision in advanced CKD is potentially harmful. Vitamin D on dialysis: hemodialysis and peritoneal dialysis patients have essentially no residual kidney calcitriol production and require activated vitamin D therapy for PTH management. Intravenous calcitriol or paricalcitol administration during dialysis sessions is common, allowing precise dosing and monitoring. Dialysis patients should not take additional vitamin D supplements beyond what is prescribed without discussing with the dialysis team. The KDIGO CKD-MBD guidelines are the authoritative reference for practitioners — available at the KDIGO CKD-MBD guidelines page.
Vitamin D Beyond Bone: Cardiovascular, Immune, and CKD Progression Effects
Beyond its classical role in calcium-phosphorus metabolism and bone health, vitamin D has pleiotropic (wide-ranging) effects throughout the body that are particularly relevant in CKD, where cardiovascular disease, immune dysfunction, and progressive kidney injury are major sources of morbidity. Cardiovascular effects of vitamin D deficiency in CKD: cardiovascular disease is the leading cause of death in CKD patients — a risk far exceeding what is explained by traditional cardiovascular risk factors alone. Vitamin D deficiency has been associated in observational studies with left ventricular hypertrophy, arterial stiffness, endothelial dysfunction, and elevated inflammatory markers — all of which are prevalent in CKD patients with poor vitamin D status. The proposed mechanisms include vitamin D’s role in suppressing the renin-angiotensin-aldosterone system (RAAS), reducing myocardial fibrosis, and regulating inflammatory cytokine production. Clinical trials of activated vitamin D therapy in CKD have examined whether these theoretical cardiovascular benefits translate into clinical outcomes. The results have been mixed — some trials showing reductions in left ventricular hypertrophy, others showing no cardiovascular benefit or even potential harm from aggressive vitamin D receptor activation. A 2023 meta-analysis of VDRA therapy in CKD patients found reductions in proteinuria and improvements in PTH control but inconclusive effects on major cardiovascular outcomes. Vitamin D and CKD progression: the question of whether correcting vitamin D deficiency slows CKD progression has been studied in multiple trials. The rationale is supported by lab data: calcitriol suppresses the RAAS, reduces TGF-beta-mediated fibrosis, and has anti-inflammatory effects in kidney tubular cells. Several randomized trials have examined VDRA therapy for its effect on proteinuria (a key marker of kidney injury) and found modest reductions, consistent with RAAS suppression effects. Whether VDRA therapy slows eGFR decline — the clinically meaningful endpoint — has not been definitively established in large, well-powered trials. The VITAL-DKD study and related trials continue to examine vitamin D supplementation effects on kidney outcomes in the general population and in CKD patients specifically. Immune function and infection risk in CKD: vitamin D plays a significant role in innate immune function — calcitriol induces the production of antimicrobial peptides (defensins and cathelicidins) in macrophages and epithelial cells, and regulates the adaptive immune response in ways that may reduce autoimmune activity and improve infection resistance. CKD patients have impaired immune responses to both infection and vaccination, partly attributed to vitamin D deficiency. Studies in hemodialysis patients have found that low 25-OHD levels are associated with higher rates of infection-related hospitalizations and mortality, though whether supplementation improves these outcomes requires larger prospective trials. Influenza and pneumococcal vaccine responses may be attenuated in vitamin D-deficient CKD patients, and correction of deficiency before vaccination is theoretically beneficial. Vitamin D and mental health in CKD: depression and cognitive decline are highly prevalent in CKD patients. Vitamin D receptors are widely expressed in the brain, and vitamin D deficiency has been associated with depression and cognitive impairment in the general population. Whether correcting vitamin D deficiency improves mental health outcomes in CKD specifically has not been well-studied, but the high prevalence of both vitamin D deficiency and depression in CKD patients makes this an area worth monitoring — discussed further in the article on kidney disease and mental health. For older CKD patients, where fall prevention is a significant concern, the classical benefit of adequate vitamin D for muscle strength and fall prevention applies in CKD just as in the general population — the article on kidney disease and healthy aging covers fall prevention in the CKD context. The StatPearls reference on vitamin D deficiency is at the StatPearls vitamin D deficiency page. The NKF resource on kidney disease and bone disease is available at the NKF mineral and bone disorder page.
Sources: NIDDK Mineral and Bone Disorder · National Kidney Foundation · StatPearls: Vitamin D Deficiency · KDIGO CKD-MBD Guidelines
Practical Patient Guide: Navigating Vitamin D Supplementation with Kidney Disease
For patients with CKD who want to understand their own vitamin D management, several practical points help translate the biochemistry into actionable knowledge for clinic visits and supplement decisions. What to ask at your next nephrology appointment: if vitamin D has never been discussed, ask whether a serum 25-OHD level has been checked recently. If the answer is no, ask whether it should be. If serum 25-OHD is low (below 20 ng/mL), ask whether supplementation with vitamin D3 is appropriate and what dose the care team recommends given the CKD stage and current mineral/bone labs. If already on activated vitamin D (calcitriol, paricalcitol, or alfacalcidol), understand what PTH target the care team is aiming for and how frequently labs will be monitored. If on dialysis, understand that vitamin D management is typically integrated into the dialysis prescription rather than being a separately self-managed supplement. Over-the-counter vitamin D3 in CKD: when it is and is not appropriate: in early CKD (stage G1–G3a) with nutritional 25-OHD deficiency and normal or mildly elevated PTH, standard over-the-counter vitamin D3 supplementation at doses of 1000–2000 IU daily is generally safe and appropriate — the kidney still has enough activation capacity to make use of the substrate. However, as CKD progresses to G3b–G5 and PTH becomes elevated, the decision to use vitamin D3 versus activated vitamin D, and at what doses, should be guided by lab monitoring rather than self-prescribed. Taking high-dose vitamin D3 (above 4000 IU/day) without monitoring in advanced CKD can cause hypercalcemia and worsen vascular calcification — precisely the outcomes that proper vitamin D management aims to prevent. What “vitamin D toxicity” means and why it matters in CKD: vitamin D toxicity (hypervitaminosis D) is rare with sunlight exposure (the skin limits further vitamin D production as stores fill) but can occur with very high-dose supplement intake (typically above 10,000 IU/day for extended periods). In CKD, the concern is somewhat different: the failure mode is not necessarily high serum 25-OHD levels causing toxicity, but rather the inappropriate use of activated vitamin D preparations (calcitriol, paricalcitol) driving hypercalcemia and hyperphosphatemia. These activated preparations are prescriptions, not over-the-counter products, precisely because their calcium-raising effects require monitoring. Patients should not supplement with calcitriol or similar prescription activated vitamin D products unless specifically prescribed — they are not equivalent to standard vitamin D3 supplements and should not be treated as interchangeable. Vitamin D-rich foods in the CKD diet: dietary sources of vitamin D include fatty fish (salmon, mackerel, sardines), egg yolks, liver, and vitamin D-fortified foods (milk, orange juice, cereals). For CKD patients with phosphorus or potassium restrictions, dairy products and some fortified foods may need to be limited — which inadvertently reduces dietary vitamin D intake. The renal dietitian can help identify vitamin D-containing foods compatible with the individual patient’s dietary restrictions. In practice, dietary vitamin D intake is rarely sufficient to meet requirements, making supplementation (in the appropriate form and dose for the CKD stage) the primary route of deficiency correction for most CKD patients. Sunlight exposure and vitamin D in CKD: sunlight is the most efficient source of vitamin D3, and regular sun exposure to the arms and legs for 10–15 minutes several times per week (without sunscreen on the exposed areas during those minutes) can meaningfully contribute to vitamin D status. However, CKD patients with comorbid conditions that require avoiding sunlight (photosensitive skin conditions, immunosuppressive medications that increase skin cancer risk including tacrolimus and mycophenolate in transplant recipients) should not use sun exposure as a vitamin D strategy without specific guidance from their care team. For post-transplant patients on immunosuppressive therapy, supplemental vitamin D rather than sunlight is typically the safer route to maintaining adequate levels. Connecting vitamin D to CKD monitoring: vitamin D status monitoring is ideally integrated into the routine nephrology visit schedule rather than tracked separately — the article on kidney disease and long-term monitoring covers how mineral and bone labs including vitamin D are incorporated into the CKD monitoring schedule at each stage. Patients with CKD and osteoporosis or high fracture risk have particular reason to ensure their vitamin D status is optimized — the bone-protecting role of adequate vitamin D in CKD is discussed in the article on kidney disease and healthy aging, which covers bone health and fall prevention as components of aging well with CKD.
Vitamin D Research Frontiers: What May Change Clinical Practice
Several active research directions in vitamin D and kidney disease may influence clinical practice over the next several years, and patients who follow their CKD management closely may encounter these developments in discussion with their care team. The VITAL-DKD trial and kidney-specific outcomes: the Vitamin D and Omega-3 Trial (VITAL) — the largest randomized trial of vitamin D3 supplementation (2000 IU/day) in the general population — found reductions in autoimmune disease incidence and cancer mortality but no significant reduction in cardiovascular events. A pre-specified kidney sub-study (VITAL-DKD) examined eGFR trajectory in trial participants with early CKD and found modestly slower eGFR decline in those receiving vitamin D3 compared to placebo. While this finding is promising for early CKD management, it addresses only the nutritional repletion question (vitamin D3 supplementation in those with early CKD) rather than the activated vitamin D question (VDRA therapy for secondary hyperparathyroidism in advanced CKD), and the effect size is modest. Larger dedicated CKD trials are needed before VITAL-DKD findings change standard of care. FGF-23 as a target: FGF-23 (fibroblast growth factor 23), the phosphaturic hormone that rises early in CKD and actively suppresses calcitriol production, is increasingly recognized as a driver of cardiovascular disease in CKD independent of its effects on vitamin D and phosphorus metabolism. Elevated FGF-23 is associated with left ventricular hypertrophy, vascular stiffness, and mortality in CKD patients. Interventions targeting FGF-23 — including dietary phosphorus restriction, phosphate binders, and potentially newer FGF-23 inhibitor drugs in development — may partially restore calcitriol production by reducing the FGF-23–driven suppression of renal 1-alpha-hydroxylase. This reframes vitamin D management in CKD partly as a downstream consequence of phosphorus control, where aggressive phosphorus restriction (in diet and supplementation) may have vitamin D benefits beyond the direct phosphorus effects. Vitamin D and the gut microbiome in CKD: emerging research suggests that vitamin D status influences gut barrier function and microbiome composition — relevant in CKD where the gut-kidney axis is increasingly recognized as central to disease progression and uremic toxin accumulation, as discussed in the companion article on probiotics and urinary health. Adequate vitamin D supports tight junction integrity in intestinal epithelial cells, potentially reducing the “leaky gut” that contributes to endotoxemia in CKD. Whether vitamin D supplementation measurably improves gut barrier function and reduces uremic toxin generation in CKD patients is an active research question. Personalized vitamin D dosing: there is substantial individual variation in the serum 25-OHD response to a given dose of vitamin D3 supplementation — partly explained by genetic variants in vitamin D-binding protein, vitamin D receptors, and the CYP enzymes involved in vitamin D metabolism. Pharmacogenomic testing for vitamin D metabolism variants is not yet standard clinical practice, but in research settings it helps explain why some patients respond to low doses while others require substantially higher doses to achieve target 25-OHD levels. As genetic testing becomes more accessible, personalized vitamin D dosing based on individual metabolic factors may become more feasible in clinical practice. For now, periodic monitoring of serum 25-OHD levels every 3–6 months during repletion (and annually once stable) remains the practical approach to individualizing dose for CKD patients.
The explanation of the two separate vitamin D deficiencies — nutritional (low 25-OHD) and the CKD-specific calcitriol deficiency — finally made the two different prescriptions I have make sense. I have both a vitamin D3 capsule and a prescription for calcitriol and I’ve always been confused about why I need both. Now I understand that the D3 is filling the storage pool and the calcitriol is replacing what the kidneys can’t make anymore. My nephrologist has never explained it this clearly.
Patricia, you’ve understood it exactly right. The standard vitamin D3 supplement and the calcitriol prescription serve distinct purposes in CKD management that don’t overlap. D3 restores the 25-OHD storage pool so there’s adequate substrate available for whatever conversion capacity remains, while calcitriol directly provides the active hormone your kidneys can no longer produce in sufficient quantity. Both targets matter — low 25-OHD and inadequate calcitriol activity can coexist and both contribute to PTH elevation and bone disease risk.
The section on FGF-23 and its role in suppressing calcitriol production was new information for me. My FGF-23 has been rising for the past year and my nephrologist has been tightening my phosphorus restriction. Now I understand that there’s also a direct vitamin D angle to the phosphorus restriction — controlling phosphate reduces FGF-23 which may partially preserve calcitriol synthesis in whatever kidney capacity is left. This kind of systems-level explanation is exactly what I needed to motivate better dietary compliance.